Novartis says lung cancer drug canakinumab fails another trial

  • In US
  • 2022-08-15 06:25:30Z
  • By Reuters

ZURICH (Reuters) -Novartis said on Monday its canakinumab drug to help treat non-small cell lung cancer failed a phase III trial, the latest blow for the treatment which also fell short in a study last year.

The drug, used as an adjuvant treatment, did not meet its primary endpoint of disease-free survival, the Swiss company said.

Adjuvant treatments are additional cancer treatments after the primary one intended to lower the risk the cancer will return.

The failure in the latest trial, called Canopy A, is a setback for Novartis after canakinumab failed in a separate study last year where it was tried in combination with another drug and chemotherapy.

"Consensus expectations for this high-risk project remained zero or low with the remaining market exclusivity for canakinumab limited until 2028," said Zuercher Kantonalbank analyst Laurent Flamme.

He estimated annual sales of around 300 million Swiss francs ($317.9 million)by 2026 for the drug as an adjuvant treatment for non-small cell lung cancer.

($1 = 0.9436 Swiss francs)

(Reporting by John Revill; Editing by Christian Schmollinger and Emelia Sithole-Matarise)


More Related News

Shionogi says COVID pill trial shows reduction in symptoms
Shionogi says COVID pill trial shows reduction in symptoms

TOKYO (Reuters) -Japan's Shionogi & Co Ltd said on Wednesday its oral treatment for COVID-19 demonstrated a significant reduction in symptoms compared with a placebo in a Phase III trial in Asia. The drug, a protease inhibitor known as ensitrelvir, met its primary endpoint in a trial conducted among predominantly vaccinated patients with mild to moderate cases of COVID-19, the company said in a statement. Shionogi's shares reversed an early decline after the announcement, closing 1.1% higher in Tokyo versus a 1.5 drop in the benchmark Nikkei gauge.

Leave a Comment

Your email address will not be published. Required fields are marked with *

Cancel reply


  • majorsite
    (2022-08-16 03:17:17Z)

    I saw your article well. You seem to enjoy majorsite for some reason. We can help you enjoy more fun. Welcome anytime :-)


Top News: US